Atrial Fibrillation Treatment in Women: What Standard Protocols Miss

Atrial fibrillation is not the same disease in women as it is in men. Women with AF are older at first diagnosis, more symptomatic, at higher absolute stroke risk, and less likely to be appropriately anticoagulated. They have worse outcomes from catheter ablation not because of biology alone but because they are referred later, when atrial remodeling is more advanced and the substrate for sustained AF is more established. The sex-specific data in AF are not marginal subgroup findings; they are consistent across large registries, major randomized trials, and multiple health systems across different countries. Understanding them is not a subspecialty concern. It is basic clinical cardiology applied to the majority of older patients who present with AF.

The consequences of overlooking these differences are concrete. An underanticoagulated woman with AF who suffers an ischemic stroke experiences greater neurological disability than an equivalently underanticoagulated man, partly because she is older at stroke onset and partly because her strokes tend to be more severe. A woman who is referred for ablation at 70 with a left atrium of 5.2 cm has a substantially lower chance of procedural success than she would have had at 63 with a left atrium of 4.1 cm. The delays and undertreatment are not random variations in care; they are patterned, reproducible, and, once recognized, partially correctable.

How AF Presents Differently in Women

Women with AF are on average five to seven years older than men at first diagnosis. This age gap is not explained by differences in underlying risk factor prevalence alone; it likely reflects genuine differences in atrial electrophysiology and the hormonal influences on atrial substrate. The practical consequence is that by the time a woman is diagnosed, she has typically had AF longer than a man at equivalent disease stage, her atrium has had more time to remodel, and the window for early intervention is already partially closed.

Women with AF are substantially more symptomatic than men. Palpitations, fatigue, dyspnea, and exercise intolerance are the dominant presenting complaints in women. Men more often present with incidentally detected AF on an ECG obtained for another reason, or with predominantly exertional symptoms. The greater symptom burden in women reflects multiple factors: older age at presentation with less physiological reserve, more frequent coexistence of heart failure with preserved ejection fraction (HFpEF) as an underlying substrate, and possibly sex differences in autonomic nervous system tone and interoception.

The HFpEF connection is particularly important. Women are diagnosed with HFpEF at approximately twice the rate of men, and HFpEF creates a bidirectional relationship with AF: elevated left atrial pressure from diastolic dysfunction promotes atrial stretch and remodeling that drives AF, and AF then worsens diastolic filling by eliminating the atrial kick and increasing heart rate. This bidirectional amplification loop means that in women with both HFpEF and AF, managing one without addressing the other produces suboptimal results for both.

Women are more likely to seek medical attention for AF symptoms, which creates a paradox. They have higher symptom burden and greater motivation to seek rhythm control, yet they are less often referred for the most effective rhythm control strategy (catheter ablation) and are more often managed with rate control alone. This disconnection between symptom burden and treatment intensity is one of the most consistently documented disparities in AF care and has no clear clinical justification.

The Anticoagulation Gap

The anticoagulation gap in AF, meaning the systematic undertreatment of women with anticoagulants compared to men with equivalent or higher stroke risk, is one of the most consistently documented sex disparities in cardiovascular medicine. It has been reported in registries from North America, Europe, and Asia, across different time periods, and across both warfarin and NOAC eras.

The JACC analysis of sex disparities in anticoagulation rates for AF documented that women were less likely to receive NOAC prescriptions than men with equivalent CHA2DS2-VASc scores, even after adjusting for clinical characteristics.

The reasons proposed for this gap include older age at presentation, which may trigger physician reluctance to anticoagulate due to perceived fall risk; presentation style differences that may cause women’s AF to be perceived as less urgent; and implicit bias in clinical decision-making. None of these explanations justifies the treatment gap. Fall risk is a modifiable consideration that should be weighed against stroke risk using validated tools, not used as a reflexive reason to withhold anticoagulation from older women. The perception that women’s presentations are less urgent is precisely the kind of clinical bias that evidence is needed to correct.

The undertreatment is clinically significant because women with AF have higher absolute stroke risk than men with AF of comparable duration and comparable CHA2DS2-VASc scores, excluding the sex point itself. This is not disputed in the literature. A woman with AF who has a CHA2DS2-VASc score of 2 (excluding the female sex point) has a higher absolute stroke risk than a man with the same score of 2. Withholding anticoagulation from her produces greater absolute harm than withholding it from her male counterpart.

Bleeding risk is also modestly higher in anticoagulated women than men, but the net clinical benefit calculation (stroke prevented vs. major bleeding caused) still favors anticoagulation across the relevant risk range for women with CHA2DS2-VASc of 2 or higher. The HAS-BLED tool, designed to estimate bleeding risk, should be used to identify and address modifiable bleeding risk factors rather than as a threshold to withhold anticoagulation.

The CHA2DS2-VASc Female Sex Point

CHA2DS2-VASc assigns one point for female sex as a risk modifier, meaning the anticoagulation threshold is one point higher for women than for men: treat if score is 2 or higher rather than 1 or higher. This was intended to capture the epidemiological observation that female sex modifies stroke risk in AF, with women carrying higher absolute risk.

The implementation has generated controversy because it means that a woman with AF and no other risk factors has a CHA2DS2-VASc score of 1 due to sex alone and falls below the anticoagulation threshold. ESC 2020 AF guidelines explicitly state that female sex alone (score of 1) should not be used as an indication for anticoagulation. The intent was to add female sex as a risk modifier to be considered when other risk factors are present, not to trigger anticoagulation in otherwise low-risk younger women with AF.

The practical implication is more straightforward than the controversy suggests. Most women who present with clinically significant AF are over 65 and have at least one additional risk factor, placing them at CHA2DS2-VASc of 3 or higher. The debate about the female sex point is largely theoretical for the majority of clinical presentations. What matters concretely is that women at CHA2DS2-VASc of 2 or higher, which is essentially all women with AF and hypertension or diabetes or age over 65, should receive anticoagulation, and the evidence is that many of them do not.

Some guidelines and expert commentaries have proposed removing the female sex point entirely and accepting that women will require fewer additional risk factors before reaching the treatment threshold. This approach is debated and not yet reflected in major guideline documents, but it reflects the underlying consensus that female sex genuinely modifies AF stroke risk and that the current scoring system may not optimally capture this.

NOAC Choices: Sex Matters in the Evidence

The four direct oral anticoagulants approved for stroke prevention in non-valvular AF, apixaban, rivaroxaban, edoxaban, and dabigatran, have each been tested in large randomized trials with approximately 15,000 to 21,000 participants. Sex-disaggregated analyses from these trials are available and clinically informative, though the trials were not powered for sex-specific endpoints and interactions should be interpreted with appropriate caution.

Apixaban (ARISTOTLE trial): apixaban showed superiority over warfarin in stroke reduction and significantly lower rates of major bleeding, intracranial hemorrhage in particular. Sex-disaggregated analyses from ARISTOTLE have generally shown consistent benefit in women, with no significant interaction by sex for the primary stroke and systemic embolism endpoint or for the major bleeding endpoint. The favorable bleeding profile is particularly relevant to women, who have somewhat higher absolute intracranial hemorrhage risk with warfarin than men at equivalent INR values.

Edoxaban (ENGAGE AF-TIMI 48 trial): the higher dose edoxaban regimen showed a signal toward attenuated stroke reduction in women compared to men in some subgroup analyses, though the interaction was not statistically significant. This observation has led some cardiologists to weigh the edoxaban sex subgroup data alongside the patient’s overall clinical profile when selecting a NOAC. It does not constitute a contraindication but is a factor in shared decision-making.

Dabigatran (RE-LY trial): data were generally consistent across sexes. Dabigatran requires twice-daily dosing and should be used cautiously in patients with eGFR below 30; it is renally cleared to a greater extent than apixaban, which has implications for older women with CKD.

Warfarin remains appropriate in specific contexts including valvular AF (mechanical valve or rheumatic mitral stenosis), where NOACs are contraindicated. Women on warfarin show more time-in-therapeutic-range instability than men on average, partly attributable to dietary variability and drug-drug interactions. This TTR instability directly increases both stroke and bleeding risk, making the switch to NOACs particularly beneficial in women who have had difficulty maintaining therapeutic INR on warfarin. For most women with non-valvular AF who are starting anticoagulation, apixaban is a reasonable default given the breadth of supporting sex-subgroup data.

QT Risk and Antiarrhythmic Drugs

Women have a longer baseline QTc interval than men by approximately 10 to 20 milliseconds. This is one of the most reproducible sex differences in cardiac electrophysiology and is attributable to sex hormone effects on cardiac ion channel expression, particularly the rapid delayed rectifier potassium current (IKr). Longer baseline QTc provides less margin before drug-induced QT prolongation reaches the threshold for dangerous arrhythmia.

Drug-induced torsades de pointes, the polymorphic ventricular tachycardia triggered by QT prolongation, is two to three times more common in women than men taking QT-prolonging antiarrhythmic drugs. This is a clinically consequential risk difference that affects drug selection in women with AF who need rhythm control pharmacotherapy.

Class III antiarrhythmics, sotalol and dofetilide, are among the drugs most commonly associated with QT-related torsades. Both are used for AF rhythm control. The risk in women argues for careful baseline QTc assessment before initiation, more conservative dosing, and closer early monitoring. Dofetilide initiation requires mandatory in-hospital monitoring for three to five days precisely because of QTc prolongation risk; the risk profile in women provides additional reason to follow this requirement rigorously. Sotalol should generally be avoided in women with baseline QTc above 440 milliseconds.

Dronedarone, a modified amiodarone analogue without the iodine moiety that causes thyroid and pulmonary toxicity, has a more favorable QT-risk profile than sotalol and dofetilide. The ATHENA trial demonstrated that dronedarone reduced cardiovascular hospitalization and death in AF patients with at least one additional cardiovascular risk factor, with consistent effects across sexes. Dronedarone does prolong QTc but to a lesser degree than sotalol and without the same torsades risk at therapeutic doses.

Class IC drugs, flecainide and propafenone, are appropriate for rhythm control in AF without structural heart disease. They do not significantly prolong QTc and therefore do not carry the sex-specific torsades risk that Class III agents carry. However, they are contraindicated in structural heart disease including LV dysfunction, significant hypertrophy, and coronary artery disease. In women with lone AF and a normal echocardiogram, a Class IC agent may be the pharmacological rhythm control option with the most favorable risk profile.

Baseline QTc measurement before initiating any antiarrhythmic drug is standard practice, and the threshold for concern is typically QTc above 450 milliseconds in women (some guidelines use 460 milliseconds). Repeat ECG within one to two weeks of initiation captures early drug-induced QTc changes before they reach dangerous levels.

Ablation: Why Women Have Worse Outcomes

Pulmonary vein isolation by catheter ablation is the most effective strategy for restoring and maintaining sinus rhythm in paroxysmal and persistent AF. Guidelines now support ablation as a first-line rhythm control option in symptomatic AF when the patient and physician agree this is the preferred approach, not merely as a last resort after antiarrhythmic drug failure. Success rates (freedom from AF at 12 months without antiarrhythmic drugs) are approximately 60 to 70 percent for paroxysmal AF and somewhat lower for persistent AF in most series.

Women have consistently lower ablation success rates and higher procedural complication rates than men. A meta-analysis of sex differences in AF ablation outcomes found that women had significantly lower rates of freedom from AF at follow-up and significantly higher rates of procedural complications, including cardiac tamponade requiring pericardiocentesis.

The dominant explanation for the outcome gap is not biological but logistical: women are referred for ablation at older ages, with longer histories of uncontrolled AF, larger left atria, and more extensive atrial fibrosis than men at the time of their first ablation. Left atrial size above 4.5 centimeters is a strong predictor of ablation failure. By the time many women reach the ablation suite, their left atrial diameter is already in this unfavorable range.

The higher rate of cardiac tamponade in women is likely attributable to smaller left atrial wall thickness, which may make transseptal puncture and catheter manipulation more hazardous. Smaller body size also affects vascular access: women have smaller femoral veins, which can complicate sheath placement, and longer procedure times from access difficulties that increase radiation exposure and contrast dose.

Earlier referral of symptomatic women to ablation evaluation, at the point of AF diagnosis rather than after antiarrhythmic drug failure, would likely narrow the outcome gap. The current practice pattern of reserving ablation for patients who have failed pharmacological management is not specified in current guidelines and results in women with ongoing symptoms, enlarged left atria, and worsening AF burden being referred at a stage where ablation is less likely to succeed.

Rate Control vs Rhythm Control

The AFFIRM trial, published in 2002, found no significant difference in total mortality between rate control and rhythm control strategies in patients with AF and one or more stroke risk factors. This result led to rate control becoming the dominant strategy for many patients with AF, particularly older patients.

The EAST-AFNET 4 trial substantially updated this picture. Early rhythm control, defined as initiation of rhythm control therapy within one year of AF diagnosis in patients with cardiovascular risk factors, reduced a composite endpoint of cardiovascular death, stroke, and hospitalization for worsening heart failure or acute coronary syndrome by 21 percent compared to usual care (predominantly rate control).

Women enrolled in EAST-AFNET 4 showed consistent directional benefit from early rhythm control, and the trial’s findings argue strongly for engaging rhythm control earlier in the AF disease course rather than waiting for symptoms to become intolerable or for rate control to fail. Given women’s greater symptom burden with AF and the evidence that earlier rhythm control improves outcomes, the combination argues for a more proactive rhythm control strategy in women with newly diagnosed AF, provided they do not have contraindications.

Rate control remains appropriate when rhythm control is not feasible, not tolerated, or not desired by the patient. Beta-blockers (metoprolol, bisoprolol) are first-line rate control agents in most women with AF. Calcium channel blockers (diltiazem, verapamil) are an alternative but should not be used in women with reduced ejection fraction. Digoxin carries a mortality signal in some observational datasets and is associated with higher toxicity risk in women at equivalent doses compared to men, likely because of lower body weight and reduced volume of distribution. Digoxin is generally reserved for patients who cannot tolerate beta-blockers or calcium channel blockers, with careful attention to dose and renal function in older women.

The Postmenopausal Transition

The incidence of AF rises with age in both sexes, but there is epidemiological evidence suggesting that the menopause transition represents an inflection point in women’s AF risk beyond what age alone would predict. Estrogen has measurable effects on atrial electrophysiology, including modulation of calcium channel expression, potassium channel activity, and atrial fibrosis pathways. The decline in estrogen after menopause may alter atrial substrate in ways that increase AF susceptibility.

Observational studies comparing AF incidence in premenopausal and postmenopausal women of similar ages have suggested a postmenopausal elevation in AF risk, though the evidence base is observational and confounded by the fact that older women are also more likely to have hypertension, sleep-disordered breathing, and structural heart disease. Disentangling the hormonal contribution from the age-related risk factor burden is methodologically challenging.

What is well-established is that the perimenopause and early postmenopause period is associated with rising blood pressure, worsening sleep quality, increased prevalence of obstructive sleep apnea, and weight gain: all independent AF risk factors. Blood pressure elevation increases left atrial pressure and promotes atrial stretch and remodeling. Sleep apnea causes repetitive episodes of hypoxia and autonomic activation that strain the atrial myocardium. Managing these drivers during the perimenopause transition is a reasonable preventive strategy, though evidence for AF-specific outcomes from such interventions is limited.

Hormone replacement therapy and AF: observational data on HRT and AF risk are inconsistent, with some studies suggesting neutral or slightly protective effects and others suggesting increased risk. HRT should not be initiated or continued specifically for AF risk reduction; the data do not support this application, and HRT carries its own cardiovascular risk profile that must be considered in its own right. The framing should be symptom management for menopausal symptoms, not AF prevention.

Synthesis: Clinical Implications of Sex-Specific AF Data

The clinical implications of the sex-specific AF literature converge on a small number of concrete practice changes that do not require new technology or new medications. They require recognizing that the standard AF management template was built largely on data from male-predominant populations and that applying it uniformly to women produces systematically worse outcomes at several decision points.

Anticoagulation should be initiated in women with CHA2DS2-VASc of 2 or higher without reflexive hesitation based on age or fall risk. Apixaban has the broadest supporting sex-subgroup data among the NOACs. Rhythm control should be offered earlier in the disease course, consistent with EAST-AFNET 4, rather than reserved for patients who have failed multiple rate control strategies. Ablation referral should occur when left atrial size is still favorable, which in practice means earlier in the AF course, not after years of failed pharmacological attempts. QT interval should be measured before antiarrhythmic drug selection, and the sex-specific torsades risk of Class III agents should explicitly inform drug choice in women with borderline or elevated baseline QTc.

None of these recommendations requires a fundamental departure from evidence-based AF management. They require applying the existing evidence with attention to the patient’s sex, which is a variable that consistently predicts different risk, different presentation, different complications, and different treatment responses. The data are not marginal; they are the data from the same pivotal trials that inform standard care, disaggregated by a variable that should routinely be considered. The gap between what the evidence supports and what women with AF actually receive in clinical practice is not a knowledge gap. It is an application gap, and recognizing it is the first step toward closing it.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.